These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 33434858)

  • 41. Detection of mucopolysaccharidosis type I heterozygotes based on the biochemical characteristics of leukocyte alpha-L-iduronidase.
    Mandelli J; Wajner A; Pires RF; Giugliani R; Coelho JC
    Arch Med Res; 2002; 33(1):20-4. PubMed ID: 11825626
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Platelets are efficient and protective depots for storage, distribution, and delivery of lysosomal enzyme in mice with Hurler syndrome.
    Dai M; Han J; El-Amouri SS; Brady RO; Pan D
    Proc Natl Acad Sci U S A; 2014 Feb; 111(7):2680-5. PubMed ID: 24550296
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Neonatal bone marrow transplantation prevents bone pathology in a mouse model of mucopolysaccharidosis type I.
    Pievani A; Azario I; Antolini L; Shimada T; Patel P; Remoli C; Rambaldi B; Valsecchi MG; Riminucci M; Biondi A; Tomatsu S; Serafini M
    Blood; 2015 Mar; 125(10):1662-71. PubMed ID: 25298037
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mucopolysaccharidosis type I: Identification and characterization of mutations affecting alpha-L-iduronidase activity.
    Lee-Chen GJ; Lin SP; Chen IS; Chang JH; Yang CW; Chin YW
    J Formos Med Assoc; 2002 Jun; 101(6):425-8. PubMed ID: 12189649
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Characterization and downstream mannose phosphorylation of human recombinant α-L-iduronidase produced in Arabidopsis complex glycan-deficient (cgl) seeds.
    He X; Pierce O; Haselhorst T; von Itzstein M; Kolarich D; Packer NH; Gloster TM; Vocadlo DJ; Qian Y; Brooks D; Kermode AR
    Plant Biotechnol J; 2013 Dec; 11(9):1034-43. PubMed ID: 23898885
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Recombinant encapsulated cells overexpressing alpha-L-iduronidase correct enzyme deficiency in human mucopolysaccharidosis type I cells.
    Baldo G; Quoos Mayer F; Burin M; Carrillo-Farga J; Matte U; Giugliani R
    Cells Tissues Organs; 2012; 195(4):323-9. PubMed ID: 21778683
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Lipid composition of whole brain and cerebellum in Hurler syndrome (MPS IH) mice.
    Heinecke KA; Peacock BN; Blazar BR; Tolar J; Seyfried TN
    Neurochem Res; 2011 Sep; 36(9):1669-76. PubMed ID: 21253856
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Targeting a Pre-existing Anti-transgene T Cell Response for Effective Gene Therapy of MPS-I in the Mouse Model of the Disease.
    Squeri G; Passerini L; Ferro F; Laudisa C; Tomasoni D; Deodato F; Donati MA; Gasperini S; Aiuti A; Bernardo ME; Gentner B; Naldini L; Annoni A; Biffi A; Gregori S
    Mol Ther; 2019 Jul; 27(7):1215-1227. PubMed ID: 31060789
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Enzyme replacement therapy started at birth improves outcome in difficult-to-treat organs in mucopolysaccharidosis I mice.
    Baldo G; Mayer FQ; Martinelli BZ; de Carvalho TG; Meyer FS; de Oliveira PG; Meurer L; Tavares A; Matte U; Giugliani R
    Mol Genet Metab; 2013 May; 109(1):33-40. PubMed ID: 23562162
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Factors influencing transfection efficiency of pIDUA/nanoemulsion complexes in a mucopolysaccharidosis type I murine model.
    Fraga M; de Carvalho TG; Bidone J; Schuh RS; Matte U; Teixeira HF
    Int J Nanomedicine; 2017; 12():2061-2067. PubMed ID: 28352175
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Improved retroviral vector design results in sustained expression after adult gene therapy in mucopolysaccharidosis I mice.
    Herati RS; Ma X; Tittiger M; Ohlemiller KK; Kovacs A; Ponder KP
    J Gene Med; 2008 Sep; 10(9):972-82. PubMed ID: 18613275
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Neonatal combination therapy improves some of the clinical manifestations in the Mucopolysaccharidosis type I murine model.
    Santi L; De Ponti G; Dina G; Pievani A; Corsi A; Riminucci M; Khan S; Sawamoto K; Antolini L; Gregori S; Annoni A; Biondi A; Quattrini A; Tomatsu S; Serafini M
    Mol Genet Metab; 2020 Jul; 130(3):197-208. PubMed ID: 32439268
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Salivary α-Iduronidase Activity as a Potential New Biomarker for the Diagnosis and Monitoring the Effect of Therapy in Mucopolysaccharidosis Type I.
    van Doorn J; van den Broek BTA; Geboers AJ; Kuiper GA; Boelens JJ; van Hasselt PM
    Biol Blood Marrow Transplant; 2018 Sep; 24(9):1808-1813. PubMed ID: 29906569
    [TBL] [Abstract][Full Text] [Related]  

  • 54.
    De Filippis C; Napoli B; Rigon L; Guarato G; Bauer R; Tomanin R; Orso G
    Cells; 2021 Dec; 11(1):. PubMed ID: 35011691
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Identification and characterization of 13 new mutations in mucopolysaccharidosis type I patients.
    Matte U; Yogalingam G; Brooks D; Leistner S; Schwartz I; Lima L; Norato DY; Brum JM; Beesley C; Winchester B; Giugliani R; Hopwood JJ
    Mol Genet Metab; 2003 Jan; 78(1):37-43. PubMed ID: 12559846
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Murine mucopolysaccharidosis type I: targeted disruption of the murine alpha-L-iduronidase gene.
    Clarke LA; Russell CS; Pownall S; Warrington CL; Borowski A; Dimmick JE; Toone J; Jirik FR
    Hum Mol Genet; 1997 Apr; 6(4):503-11. PubMed ID: 9097952
    [TBL] [Abstract][Full Text] [Related]  

  • 57. An algorithm to predict phenotypic severity in mucopolysaccharidosis type I in the first month of life.
    Kingma SD; Langereis EJ; de Klerk CM; Zoetekouw L; Wagemans T; IJlst L; Wanders RJ; Wijburg FA; van Vlies N
    Orphanet J Rare Dis; 2013 Jul; 8():99. PubMed ID: 23837464
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Progressive heart disease in mucopolysaccharidosis type I mice may be mediated by increased cathepsin B activity.
    Baldo G; Tavares AM; Gonzalez E; Poletto E; Mayer FQ; Matte UD; Giugliani R
    Cardiovasc Pathol; 2017; 27():45-50. PubMed ID: 28104572
    [TBL] [Abstract][Full Text] [Related]  

  • 59. p.X654R IDUA variant among Thai individuals with intermediate mucopolysaccharidosis type I and its residual activity as demonstrated in COS-7 cells.
    Ngiwsara L; Ketudat-Cairns JR; Sawangareetrakul P; Charoenwattanasatien R; Champattanachai V; Kuptanon C; Pangkanon S; Tim-Aroon T; Wattanasirichaigoon D; Svasti J
    Ann Hum Genet; 2018 May; 82(3):150-157. PubMed ID: 29282708
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Phenotypic characterisation of the Mucopolysaccharidosis Type I (MPSI) Idua-W392X mouse model reveals increased anxiety-related traits in female mice.
    Andreou T; Ishikawa-Learmonth Y; Bigger BW
    Mol Genet Metab; 2023 Aug; 139(4):107651. PubMed ID: 37473537
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.